Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Therapeutic efficacy of a combination of mesalazine and Bifid Triple Viable Capsules (BTVCs) on ulcerative colitis patients, and its effect on inflammation and oxidative stress

Lina Wei, Hua Xu

Department of Gastroenterology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, China;

For correspondence:- Hua Xu Email: x1k3fl@163.com Tel:+8641184671291

Accepted: 29 September 2021 Published: 31 October 2021

Citation: Wei L, Xu H. Therapeutic efficacy of a combination of mesalazine and Bifid Triple Viable Capsules (BTVCs) on ulcerative colitis patients, and its effect on inflammation and oxidative stress. Trop J Pharm Res 2021; 20(10):2213-2218 doi: 10.4314/tjpr.v20i10.28

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the curative impact of mesalazine (MSZ)-BTVCs combination on ulcerative colitis (UC), and its influence on inflammation and oxidative stress in the patients.

Methods: 100 UC patients were randomely assigned to a control group given MSZ capsule treatment only, and a combination group treated with BTVCs and MSZ. Treatment effectiveness, inflammatory response, and oxidative stress in the two groups before and after treatment were compared.

Results: The combination group had higher total effectiveness than the control group. The serum levels of MDA, high-sensitivity C-reactive protein (hs-CRP), TNF-α and interleukin-6 (IL-6) were lower, while serum levels of superoxide dismutase (SOD) and interleukin-10 (IL-10) were markedly increased in patients given combination treatment, when compared with controls. Pre-drug exposure UC disease activity index (UC-DAI) and clinical symptom scores were similar in both cohorts of patients, but the post-treatment scores were statistically decreased, especially in the combination group.

Conclusion: The combined use of MSZ and BTVCs was more effective against UC than monotherapy, as it effectively relieved inflammation and oxidative stress in patients, resulting in better clinical efficacy.

Keywords: MSZ, BTVCs, Ulcerative colitis, Inflammation, Oxidative stress